Selected research
Industry Research
mRNA Vaccines for Infectious Diseases Industry Research Report 2026
Market perspective
The global mRNA Vaccines for Infectious Diseases market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the mRNA Vaccines for Infectious Diseases market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the mRNA Vaccines for Infectious Diseases market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the mRNA Vaccines for Infectious Diseases market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of mRNA Vaccines for Infectious Diseases include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global mRNA Vaccines for Infectious Diseases market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to mRNA Vaccines for Infectious Diseases.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
mRNA Vaccines for Infectious Diseases Market by Company
Translate Bio
Tiba Biotechnology
Sangamo Therapeutics
Moderna Therapeutics
In-Cell-Art
Ethris
eTheRNA
CureVac
BioNTech
Argos Therapeutics
mRNA Vaccines for Infectious Diseases Segment by Type
Infectious Disease Vaccines
Cancer Vaccines
mRNA Vaccines for Infectious Diseases Segment by Application
Infectious Disease
Cancer
mRNA Vaccines for Infectious Diseases Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccines for Infectious Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccines for Infectious Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccines for Infectious Diseases.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of mRNA Vaccines for Infectious Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Infectious Disease Vaccines
- Cancer Vaccines
Applications
- Infectious Disease
- Cancer
Companies covered
- Translate Bio
- Tiba Biotechnology
- Sangamo Therapeutics
- Moderna Therapeutics
- In-Cell-Art
- Ethris
- eTheRNA
- CureVac
- BioNTech
- Argos Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 mRNA Vaccines for Infectious Diseases by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Infectious Disease Vaccines
- 2.2.3 Cancer Vaccines
- 2.3 mRNA Vaccines for Infectious Diseases by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Infectious Disease
- 2.3.3 Cancer
- 2.4 Assumptions and Limitations
3 mRNA Vaccines for Infectious Diseases Breakdown Data by Type
- 3.1 Global mRNA Vaccines for Infectious Diseases Historic Market Size by Type (2021-2026)
- 3.2 Global mRNA Vaccines for Infectious Diseases Forecasted Market Size by Type (2027-2032)
4 mRNA Vaccines for Infectious Diseases Breakdown Data by Application
- 4.1 Global mRNA Vaccines for Infectious Diseases Historic Market Size by Application (2021-2026)
- 4.2 Global mRNA Vaccines for Infectious Diseases Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global mRNA Vaccines for Infectious Diseases Market Perspective (2021-2032)
- 5.2 Global mRNA Vaccines for Infectious Diseases Growth Trends by Region
- 5.2.1 Global mRNA Vaccines for Infectious Diseases Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 mRNA Vaccines for Infectious Diseases Historic Market Size by Region (2021-2026)
- 5.2.3 mRNA Vaccines for Infectious Diseases Forecasted Market Size by Region (2027-2032)
- 5.3 mRNA Vaccines for Infectious Diseases Market Dynamics
- 5.3.1 mRNA Vaccines for Infectious Diseases Industry Trends
- 5.3.2 mRNA Vaccines for Infectious Diseases Market Drivers
- 5.3.3 mRNA Vaccines for Infectious Diseases Market Challenges
- 5.3.4 mRNA Vaccines for Infectious Diseases Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top mRNA Vaccines for Infectious Diseases Players by Revenue
- 6.1.1 Global Top mRNA Vaccines for Infectious Diseases Players by Revenue (2021-2026)
- 6.1.2 Global mRNA Vaccines for Infectious Diseases Revenue Market Share by Players (2021-2026)
- 6.2 Global mRNA Vaccines for Infectious Diseases Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of mRNA Vaccines for Infectious Diseases Head Office and Area Served
- 6.4 Global mRNA Vaccines for Infectious Diseases Players, Product Type & Application
- 6.5 Global mRNA Vaccines for Infectious Diseases Manufacturers Established Date
- 6.6 Global mRNA Vaccines for Infectious Diseases Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America mRNA Vaccines for Infectious Diseases Market Size (2021-2032)
- 7.2 North America mRNA Vaccines for Infectious Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America mRNA Vaccines for Infectious Diseases Market Size by Country (2021-2026)
- 7.4 North America mRNA Vaccines for Infectious Diseases Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe mRNA Vaccines for Infectious Diseases Market Size (2021-2032)
- 8.2 Europe mRNA Vaccines for Infectious Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe mRNA Vaccines for Infectious Diseases Market Size by Country (2021-2026)
- 8.4 Europe mRNA Vaccines for Infectious Diseases Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific mRNA Vaccines for Infectious Diseases Market Size (2021-2032)
- 9.2 Asia-Pacific mRNA Vaccines for Infectious Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific mRNA Vaccines for Infectious Diseases Market Size by Country (2021-2026)
- 9.4 Asia-Pacific mRNA Vaccines for Infectious Diseases Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America mRNA Vaccines for Infectious Diseases Market Size (2021-2032)
- 10.2 South America mRNA Vaccines for Infectious Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America mRNA Vaccines for Infectious Diseases Market Size by Country (2021-2026)
- 10.4 South America mRNA Vaccines for Infectious Diseases Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size (2021-2032)
- 11.2 Middle East & Africa mRNA Vaccines for Infectious Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Country (2021-2026)
- 11.4 Middle East & Africa mRNA Vaccines for Infectious Diseases Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Translate Bio
- 12.1.1 Translate Bio Company Information
- 12.1.2 Translate Bio Business Overview
- 12.1.3 Translate Bio Revenue in mRNA Vaccines for Infectious Diseases Business (2021-2026)
- 12.1.4 Translate Bio mRNA Vaccines for Infectious Diseases Product Portfolio
- 12.1.5 Translate Bio Recent Developments
- 12.2 Tiba Biotechnology
- 12.2.1 Tiba Biotechnology Company Information
- 12.2.2 Tiba Biotechnology Business Overview
- 12.2.3 Tiba Biotechnology Revenue in mRNA Vaccines for Infectious Diseases Business (2021-2026)
- 12.2.4 Tiba Biotechnology mRNA Vaccines for Infectious Diseases Product Portfolio
- 12.2.5 Tiba Biotechnology Recent Developments
- 12.3 Sangamo Therapeutics
- 12.3.1 Sangamo Therapeutics Company Information
- 12.3.2 Sangamo Therapeutics Business Overview
- 12.3.3 Sangamo Therapeutics Revenue in mRNA Vaccines for Infectious Diseases Business (2021-2026)
- 12.3.4 Sangamo Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
- 12.3.5 Sangamo Therapeutics Recent Developments
- 12.4 Moderna Therapeutics
- 12.4.1 Moderna Therapeutics Company Information
- 12.4.2 Moderna Therapeutics Business Overview
- 12.4.3 Moderna Therapeutics Revenue in mRNA Vaccines for Infectious Diseases Business (2021-2026)
- 12.4.4 Moderna Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
- 12.4.5 Moderna Therapeutics Recent Developments
- 12.5 In-Cell-Art
- 12.5.1 In-Cell-Art Company Information
- 12.5.2 In-Cell-Art Business Overview
- 12.5.3 In-Cell-Art Revenue in mRNA Vaccines for Infectious Diseases Business (2021-2026)
- 12.5.4 In-Cell-Art mRNA Vaccines for Infectious Diseases Product Portfolio
- 12.5.5 In-Cell-Art Recent Developments
- 12.6 Ethris
- 12.6.1 Ethris Company Information
- 12.6.2 Ethris Business Overview
- 12.6.3 Ethris Revenue in mRNA Vaccines for Infectious Diseases Business (2021-2026)
- 12.6.4 Ethris mRNA Vaccines for Infectious Diseases Product Portfolio
- 12.6.5 Ethris Recent Developments
- 12.7 eTheRNA
- 12.7.1 eTheRNA Company Information
- 12.7.2 eTheRNA Business Overview
- 12.7.3 eTheRNA Revenue in mRNA Vaccines for Infectious Diseases Business (2021-2026)
- 12.7.4 eTheRNA mRNA Vaccines for Infectious Diseases Product Portfolio
- 12.7.5 eTheRNA Recent Developments
- 12.8 CureVac
- 12.8.1 CureVac Company Information
- 12.8.2 CureVac Business Overview
- 12.8.3 CureVac Revenue in mRNA Vaccines for Infectious Diseases Business (2021-2026)
- 12.8.4 CureVac mRNA Vaccines for Infectious Diseases Product Portfolio
- 12.8.5 CureVac Recent Developments
- 12.9 BioNTech
- 12.9.1 BioNTech Company Information
- 12.9.2 BioNTech Business Overview
- 12.9.3 BioNTech Revenue in mRNA Vaccines for Infectious Diseases Business (2021-2026)
- 12.9.4 BioNTech mRNA Vaccines for Infectious Diseases Product Portfolio
- 12.9.5 BioNTech Recent Developments
- 12.10 Argos Therapeutics
- 12.10.1 Argos Therapeutics Company Information
- 12.10.2 Argos Therapeutics Business Overview
- 12.10.3 Argos Therapeutics Revenue in mRNA Vaccines for Infectious Diseases Business (2021-2026)
- 12.10.4 Argos Therapeutics mRNA Vaccines for Infectious Diseases Product Portfolio
- 12.10.5 Argos Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst